Current Report Filing (8-k)
November 12 2020 - 7:01AM
Edgar (US Regulatory)
0001137883
false
0001137883
2020-11-10
2020-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 12, 2020 (November 10, 2020)
Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-36641
|
|
20-7273918
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
1325 Avenue of Americas, 28th Floor
|
|
New York, NY
|
10019
|
(Address of principal executive offices)
|
(Zip Code)
|
(201) 488-0460
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.00005 par value
|
BCLI
|
NASDAQ Stock Market LLC
(Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2020 Annual Meeting of Stockholders
(the “Annual Meeting”) of Brainstorm Cell Therapeutics Inc. (the “Company”) was held virtually via the
internet on November 10, 2020 to consider and vote on the proposals set forth below each of which is described in greater detail
in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on October 1, 2020. The
following actions were taken at the Annual Meeting:
1. The seven nominees (listed below) for
election to the Company’s Board of Directors were elected to hold office until the next annual meeting of stockholders and
until their successors are duly elected and qualified or until their earlier resignation or removal, based upon the following votes:
|
Votes For
|
Votes
Withheld
|
Votes
Against
|
Abstentions
|
Broker
Non-Votes
|
Sankesh Abbhi
|
9,346,018
|
125,190
|
N/A
|
N/A
|
13,053,806
|
Dr. Irit Arbel
|
8,216,058
|
1,255,150
|
N/A
|
N/A
|
13,053,806
|
Dr. June S. Almenoff
|
9,360,443
|
110,765
|
N/A
|
N/A
|
13,053,806
|
Dr. Anthony Polverino
|
9,046,379
|
424,829
|
N/A
|
N/A
|
13,053,806
|
Dr. Jacob Frenkel
|
9,261,030
|
210,178
|
N/A
|
N/A
|
13,053,806
|
Malcolm Taub
|
9,043,406
|
427,802
|
N/A
|
N/A
|
13,053,806
|
Uri Yablonka
|
9,314,574
|
156,634
|
N/A
|
N/A
|
13,053,806
|
2. The proposal to approve amendments to the Company’s 2014 Stock Incentive Plan and the Company’s 2014 Global Share
Option Plan to increase the shared pool of shares available for issuance under the Company’s current equity plans by 1,600,000
additional shares (from 4,000,000 to 5,600,000 shares) of Company Common Stock was approved, based upon the following votes:
Votes For
|
Votes Withheld
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
6,248,132
|
N/A
|
3,061,287
|
161,789
|
13,053,806
|
3. The proposal to ratify the appointment of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network, as the Company’s
independent registered public accounting firm for the Company’s current fiscal year was approved, based upon the following
votes:
Votes For
|
Votes Withheld
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
22,126,237
|
N/A
|
202,261
|
196,516
|
N/A
|
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
Exhibit No.
|
Description
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BRAINSTORM CELL THERAPEUTICS INC.
|
|
|
|
Date: November 12, 2020
|
By:
|
/s/ Chaim Lebovits
|
|
|
Chaim Lebovits
|
|
Chief Executive Officer
|
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024